Democratic Republic of the Congo & Merck Group

Democratic Republic of the Congo: The Democratic Republic of the Congo is the epicenter of the outbreak, facing severe health and economic strain. The vaccine arrival is a positive step, but the country continues to suffer high mortality and disruption.

Merck Group: Merck Group is the developer of Ervebo, the only approved Ebola vaccine, which is being deployed in the DRC outbreak. Its role is central, and successful cross-protection could expand its market and reputation.

Democratic Republic of the Congo: The epicenter of the outbreak, facing exponential spread, high death toll, and strained health system. The crisis is worsening, with significant humanitarian and economic implications.

Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.

Democratic Republic of the Congo: The epicenter of the outbreak, facing a public health crisis with over 2,100 deaths and strained healthcare infrastructure. The government is coordinating the response but faces challenges from conflict and unpaid health workers.

Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.